BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Troriluzole readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Troriluzole\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03970447-10774@assetmemo.bio
DTSTAMP:20261121T005420Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Troriluzole: Phase 2/3 readout est. (NCT03970447)
DESCRIPTION:Troriluzole\, phase 2/3.\nStudy: A Trial to Evaluate Multiple R
 egimens in Newly Diagnosed and Recurrent Glioblastoma\nEstimated primary c
 ompletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /troriluzole#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03970447
URL:https://assetmemo.bio/drug/troriluzole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989853-10774@assetmemo.bio
DTSTAMP:20261121T005420Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Troriluzole: Phase 1 readout est. (NCT06989853)
DESCRIPTION:Troriluzole\, phase 1.\nStudy: Methamphetamine and Troriluzole\
 nEstimated primary completion: 28 February 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/troriluzole#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06989853
URL:https://assetmemo.bio/drug/troriluzole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
